Purpose The 26S proteasome plays important roles in many intracellular processes and is
therefore a critical intracellular cellular target for anticancer treatments. The primary aim of …

The 26S proteasome is a proteolytic enzyme found in both cytoplasm and nucleus. In this
study, we examined the differential expression of proteasome inhibitor bortezomib-induced …

Doxorubicin (Dox), one of the most effective chemotherapy drug for cancer treatment, is
limited by its severe side effects and chemoresistance. Dox induces DNA damage and leads …

Numerous proteins controlling cell cycle progression, apoptosis, and angiogenesis are
degraded by the ubiquitin/proteasome system, which has become the subject for intense …

Introduction Proteasome inhibition provides an attractive approach to cancer therapy and
may have application in the treatment of breast cancer. However, results of recent clinical …

The ubiquitin‐proteasome system allows the targeted degradation of proteins and plays a
critical role in the regulation of many cellular processes. Proteasome inhibition is a recent …

The cellular and molecular effects of the proteasome inhibitor bortezomib on breast cancer
cells are as yet poorly characterized. Here, in a panel of six breast cancer cell lines …

Given that the proteasome is essential for multiple cellular processes by degrading diverse
regulatory proteins, inhibition of the proteasome has emerged as an attractive target for anti …

Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is
widely used for treatment in a number of cancers including breast cancer; however, the …

The 26S proteasome is a multicatalytic intracellular protease expressed in eukaryotic cells. It
is responsible for selective degradation of intracellular proteins that are responsible for cell …